clinical trial · NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company·phase3·active not recruiting·n = 643
ObesityRetatrutidePlacebo
brief summary
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
started
Mar 5, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Mar 3, 2026
official title
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol